Most Americans would recommend RSV immunizations for older adults, infants, pregnant women

A nationally representative APPC survey of 1,637 US adults (Nov. 17–Dec. 1, 2025) found majorities would recommend RSV vaccination for older adults (64%) and pregnant people (61%), and would recommend monoclonal antibody injections for infants in some cases (59%). The survey also found rising awareness of FDA-approved RSV products and increases in confidence about their safety.

A nationally representative survey by the Annenberg Public Policy Center (APPC) asked 1,637 US adults about RSV immunizations between November 17 and December 1, 2025. Respondents reported growing awareness of FDA-approved RSV vaccines for older adults and pregnant people, and of monoclonal antibody products for infants. The article notes RSV remains a leading cause of hospitalization among infants and a frequent cause of severe respiratory illness in older adults. Key findings: - 56% of respondents said they were aware of an FDA-approved RSV vaccine for older adults, up from 42% in October 2023. 38% said they knew of a maternal RSV vaccine, up from 12% in August 2023. - 64% said they would recommend the RSV vaccine to a friend or family member aged 75 or older or a high-risk person aged 50–74. - 61% said they would recommend the RSV vaccine to someone who is pregnant to help protect the newborn, up from 46% in September 2024. - 59% said they would recommend a monoclonal antibody injection for newborns or infants born during RSV season if the mother was not vaccinated during pregnancy, up from 46% in September 2024. - Respondents were more likely to favor maternal vaccination over infant monoclonal antibody injection to protect newborns (43% vs. 13%); 30% were unsure and 14% said they would recommend neither. 70% said it is safer for older adults to get the RSV vaccine than to get RSV, and 58% said the same for pregnant women (both up five points from February 2025). The survey’s margin of error is ±3.5 percentage points. Summary: The APPC survey indicates rising public acceptance and familiarity with RSV immunizations for older adults, pregnant people, and certain infants. The article reports that RSV activity remains elevated in parts of the United States and that federal officials have recently re-examined childhood vaccine recommendations; RSV prevention guidance for newborns is reported as effectively unchanged. Undetermined at this time.